Does the media refer more to ONCY or AKBA?

In the previous week, Akebia Therapeutics had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 11 mentions for Akebia Therapeutics and 3 mentions for Oncolytics Biotech. Akebia Therapeutics' average media sentiment score of -0.02 beat Oncolytics Biotech's score of -0.09 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate ELYM or ONCY?

Oncolytics Biotech has a consensus target price of $10.00, indicating a potential upside of 1,099.04%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, ELYM or ONCY?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is ELYM or ONCY more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Oncolytics Biotech N/A -2,185.97% -442.99%

Is ONCY or CMPX more profitable?

Compass Therapeutics' return on equity of -38.71% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Compass Therapeutics N/A -38.71% -34.72%

Does the media prefer ONCY or CMPX?

In the previous week, Compass Therapeutics had 9 more articles in the media than Oncolytics Biotech. MarketBeat recorded 12 mentions for Compass Therapeutics and 3 mentions for Oncolytics Biotech. Compass Therapeutics' average media sentiment score of 0.27 beat Oncolytics Biotech's score of -0.09 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer UPB or ONCY?

In the previous week, Upstream Bio had 11 more articles in the media than Oncolytics Biotech. MarketBeat recorded 14 mentions for Upstream Bio and 3 mentions for Oncolytics Biotech. Upstream Bio's average media sentiment score of 0.52 beat Oncolytics Biotech's score of -0.09 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, DMAC or ONCY?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is DMAC or ONCY more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Oncolytics Biotech N/A -2,185.97% -442.99%

Does the media prefer DMAC or ONCY?

In the previous week, DiaMedica Therapeutics had 17 more articles in the media than Oncolytics Biotech. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 3 mentions for Oncolytics Biotech. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Oncolytics Biotech's score of -0.09 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncolytics Biotech (ONCY) Competitors

$0.83 +0.03 (+4.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 -0.02 (-2.52%)

As of 07:02 PM Eastern

Compare

ONCY vs. AKBA, ELYM, CMPX, UPB, and DMAC

Should you buy Oncolytics Biotech stock or one of its competitors? Oncolytics Biotech's main competitors and comparable companies include Akebia Therapeutics (AKBA), Eliem Therapeutics (ELYM), Compass Therapeutics (CMPX), Upstream Bio (UPB), and DiaMedica Therapeutics (DMAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncolytics Biotech compare to Akebia Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Akebia Therapeutics had 8 more articles in the media than Oncolytics Biotech. MarketBeat recorded 11 mentions for Akebia Therapeutics and 3 mentions for Oncolytics Biotech. Akebia Therapeutics' average media sentiment score of -0.02 beat Oncolytics Biotech's score of -0.09 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than Oncolytics Biotech. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A

Oncolytics Biotech has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncolytics Biotech has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Oncolytics Biotech currently has a consensus target price of $10.00, indicating a potential upside of 1,099.04%. Akebia Therapeutics has a consensus target price of $3.75, indicating a potential upside of 324.02%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Oncolytics Biotech is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Akebia Therapeutics beats Oncolytics Biotech on 10 of the 16 factors compared between the two stocks.

How does Oncolytics Biotech compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Oncolytics Biotech had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.09 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Oncolytics Biotech	Neutral

Eliem Therapeutics' return on equity of -47.03% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

Oncolytics Biotech has a consensus target price of $10.00, indicating a potential upside of 1,099.04%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Oncolytics Biotech beats Eliem Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Compass Therapeutics?

Oncolytics Biotech (NASDAQ:ONCY) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Compass Therapeutics had 9 more articles in the media than Oncolytics Biotech. MarketBeat recorded 12 mentions for Compass Therapeutics and 3 mentions for Oncolytics Biotech. Compass Therapeutics' average media sentiment score of 0.27 beat Oncolytics Biotech's score of -0.09 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncolytics Biotech has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Compass Therapeutics	$850K	476.71	-$66.49M	-$0.40	N/A

Oncolytics Biotech has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Compass Therapeutics' return on equity of -38.71% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Compass Therapeutics	N/A	-38.71%	-34.72%

Oncolytics Biotech currently has a consensus target price of $10.00, indicating a potential upside of 1,099.04%. Compass Therapeutics has a consensus target price of $11.77, indicating a potential upside of 423.08%. Given Oncolytics Biotech's higher possible upside, equities analysts plainly believe Oncolytics Biotech is more favorable than Compass Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Compass Therapeutics beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Oncolytics Biotech compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Oncolytics Biotech has lower revenue, but higher earnings than Upstream Bio. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	135.87	-$143.44M	-$2.90	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, Upstream Bio had 11 more articles in the media than Oncolytics Biotech. MarketBeat recorded 14 mentions for Upstream Bio and 3 mentions for Oncolytics Biotech. Upstream Bio's average media sentiment score of 0.52 beat Oncolytics Biotech's score of -0.09 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncolytics Biotech has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

6.8% of Oncolytics Biotech shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Upstream Bio currently has a consensus target price of $29.67, indicating a potential upside of 319.61%. Oncolytics Biotech has a consensus target price of $10.00, indicating a potential upside of 1,099.04%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Upstream Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Summary

Upstream Bio beats Oncolytics Biotech on 9 of the 16 factors compared between the two stocks.

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

DiaMedica Therapeutics' return on equity of -77.76% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

DiaMedica Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 79.64%. Oncolytics Biotech has a consensus price target of $10.00, indicating a potential upside of 1,099.04%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

In the previous week, DiaMedica Therapeutics had 17 more articles in the media than Oncolytics Biotech. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 3 mentions for Oncolytics Biotech. DiaMedica Therapeutics' average media sentiment score of 0.75 beat Oncolytics Biotech's score of -0.09 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DiaMedica Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Summary

DiaMedica Therapeutics and Oncolytics Biotech tied by winning 7 of the 14 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCY vs. The Competition

Export

Metric	Oncolytics Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.48M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.45	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-16.68	16.78	12.91	6.24
Net Income	-$28.76M	-$13.32M	$3.45B	$347.60M
7 Day Performance	3.93%	1.74%	1.12%	1.07%
1 Month Performance	-8.17%	1.60%	1.79%	1.03%
1 Year Performance	-11.30%	56.43%	67.69%	20.77%

Oncolytics Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCY Oncolytics Biotech	1.6989 of 5 stars	$0.83 +4.3%	$10.00 +1,099.0%	-21.6%	$95.48M	N/A	N/A	30	Earnings Report
AKBA Akebia Therapeutics	1.8281 of 5 stars	$1.31 -0.8%	$4.67 +256.2%	-73.6%	$354.10M	$236.20M	N/A	430
ELYM Eliem Therapeutics	N/A	$11.90 -1.5%	N/A	+793.8%	$354.05M	N/A	N/A	9
CMPX Compass Therapeutics	2.1864 of 5 stars	$1.89 -1.3%	$12.25 +549.9%	-27.1%	$343.97M	$850K	N/A	20
UPB Upstream Bio	1.9349 of 5 stars	$6.42 +1.7%	$33.17 +416.6%	-62.8%	$343.39M	$3.32M	N/A	38	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCY) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncolytics Biotech (ONCY) Competitors

ONCY vs. AKBA, ELYM, CMPX, UPB, and DMAC

How does Oncolytics Biotech compare to Akebia Therapeutics?

Summary

How does Oncolytics Biotech compare to Eliem Therapeutics?

Summary

How does Oncolytics Biotech compare to Compass Therapeutics?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Summary

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncolytics Biotech (ONCY) Competitors

ONCY vs. AKBA, ELYM, CMPX, UPB, and DMAC

How does Oncolytics Biotech compare to Akebia Therapeutics?

Does the media refer more to ONCY or AKBA?

Which has stronger earnings and valuation, ONCY or AKBA?

Is ONCY or AKBA more profitable?

Do insiders and institutionals believe in ONCY or AKBA?

Which has more risk & volatility, ONCY or AKBA?

Do analysts recommend ONCY or AKBA?

Summary

How does Oncolytics Biotech compare to Eliem Therapeutics?

Do institutionals and insiders have more ownership in ELYM or ONCY?

Which has stronger earnings and valuation, ELYM or ONCY?

Does the media favor ELYM or ONCY?

Is ELYM or ONCY more profitable?

Do analysts rate ELYM or ONCY?

Which has more risk & volatility, ELYM or ONCY?

Summary

How does Oncolytics Biotech compare to Compass Therapeutics?

Do institutionals and insiders believe in ONCY or CMPX?

Does the media prefer ONCY or CMPX?

Which has stronger earnings & valuation, ONCY or CMPX?

Which has more volatility and risk, ONCY or CMPX?

Is ONCY or CMPX more profitable?

Do analysts recommend ONCY or CMPX?

Summary

How does Oncolytics Biotech compare to Upstream Bio?

Which has preferable valuation and earnings, UPB or ONCY?

Does the media prefer UPB or ONCY?

Is UPB or ONCY more profitable?

Do insiders and institutionals have more ownership in UPB or ONCY?

Do analysts rate UPB or ONCY?

Which has more risk and volatility, UPB or ONCY?

Summary

How does Oncolytics Biotech compare to DiaMedica Therapeutics?

Is DMAC or ONCY more profitable?

Do analysts rate DMAC or ONCY?

Do institutionals and insiders believe in DMAC or ONCY?

Which has better valuation and earnings, DMAC or ONCY?

Does the media prefer DMAC or ONCY?

Which has more risk & volatility, DMAC or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY vs. The Competition

Oncolytics Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools